Table 2:

Comparison of medication use and comorbidities at cohort entry and study end

Variable	Cohort entry		Study end

	PCOS^*	Matched controls	PCOS^*	Matched controls
Medication use, % of women

ACE inhibitor or ARB	2.18	2.57	5.06	5.10

Beta blocker	3.42	3.52	7.95	6.80

Benzodiazepine	8.93	8.06	20.77	16.95

Calcium-channel blocker	0.92	1.06	2.51	2.18

Diabetes medications	20.31	20.65	42.88	21.55

SSRI or tricyclic antidepressant	17.09	17.32	31.76	28.88

Statin or fibrate	2.45	2.79	5.79	5.23

Comorbidities, % of women

Acne	11.04	10.92	24.15	19.65

Asthma	6.93	6.92	15.32	12.82

COPD	3.34	3.45	11.45	9.29

Diabetes	6.70	8.31	14.87	12.23

Dysmenorrhea	5.79	5.71	14.23	10.95

Endometriosis	2.71	2.82	7.42	4.88

Hyperlipidemia	10.47	10.91	27.10	20.15

Hypertension	7.82	8.40	18.70	14.75

Hypothyroid	8.23	8.32	17.23	12.67

Ovarian inflammation	1.74	1.83	5.72	3.84

Vaginal inflammation	12.56	12.52	31.22	27.64

Uterine leiomyoma	2.05	2.03	5.96	4.65

Irregular menstrual cycle	40.04	40.06	72.07	54.15

Migraine	5.53	5.67	15.10	12.33

Mood or anxiety disorder	15.96	16.26	34.09	29.65

Obesity	13.35	13.32	33.11	21.04

Peptic ulcer disease	0.40	0.42	1.32	1.03

Premenstrual tension syndrome (PMS or PMDD)	1.42	1.34	4.12	2.97

Sleep disorder	0.82	0.88	3.26	1.98

Smoking	2.57	2.71	7.31	6.85

Note: ACE = angiotensin-converting enzyme, ARB = angiotensin-receptor blocker, COPD = chronic obstructive pulmonary disorder, PCOS = polycystic ovary syndrome, PMDD = premenstrual dysphoric disorder, PMS = premenstrual syndrome, SSRI = selective serotonin reuptake inhibitor.
↵* Defined as a claim for PCOS (International Classification of Disease, 9th Revision [Clinical Modification (ICD-9-CM)] 256.4).